Koblenz

• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants … Recruiting
  2022-501697-19-01 5 2024-06-18 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr … Recruiting
  2024-512320-11-00 5 2023-08-09 Primary diffuse large B-cell lymphoma of the central nervous system (P
• A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting
  2024-517966-40-00 4 2023-07-13 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
• Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w … Recruiting
  2022-501808-96-00 4 2023-05-15 Mantle Cell Lymphoma
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting
  2022-500783-35-00 5 2022-12-06 Acute Myeloid Leukemia
• International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting
  2022-501180-40-00 5 2022-06-17 Ewing Sarcoma
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl … Recruiting
  2023-506891-28-00 5 2022-05-02 The target population of interest in this study is participants with l
• SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. Recruiting
  2024-510578-25-00 5 2021-11-05 Histologically proven high-risk medulloblastoma, with any of the curre
• Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia (MOSAIC) Recruiting
  2024-514014-13-00 9 2020-09-02 female and male adult patients with acute myeloid leukemia
• International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the effica … Recruiting
  2022-501454-11-00 5 2020-02-05 standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma
• SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym … Recruiting
  2024-512222-28-00 10 2015-06-02 Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended recruitment
  2022-500571-32-00 4 2024-05-15 Early-Stage Unfavorable Classical Hodgkin Lymphoma
• 1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended recruitment
  2022-500430-29-00 5 2023-10-11 Myelodysplastic Syndrome (MDS)
• Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended recruitment
  2023-503501-11-00 5 2023-02-09 Metastatic Non-small Cell Lung Cancer
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer ( … Ended recruitment
  2023-509260-25-00 5 2022-07-12 Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended recruitment
  2023-503990-39-00 5 2021-09-30 Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
• Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended recruitment
  2024-514473-21-00 5 2021-06-21 Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer

Showing 25–48 of 79 trials